Julian Upton

The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role 
in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.

How the nation’s rapidly changing regulatory climate is creating a new landscape for pharmaceutical service providers

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

Pharm Exec speaks to Mark Lambrecht, Director of the Health and Life Sciences Global Practice at SAS, about the growing role of big data analytics in pharma and how the industry is evolving to keep pace with it.

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Sonalee Agarwal, head of value and evidence strategy for Alnylam, talks with Pharm Exec about the role of real-world evidence in the rare and ultra-rare disease space.